References
- Betten DP, Vohra RB, Cook MD, et al. Antidote use in the critically ill poisoned patient. J Intensive Care Med. 2006;21:255–277.
- Walker WE, Levy RC, Hanenson IB. Physostigmine-its use and abuse. JACEP. 1976;5:436–439.
- Schneir AB, Offerman SR, Ly BT, et al. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med. 2003;42:14–19.
- Greene LT. Physostigmine treatment of anticholinergic-drug depression in postoperative patients. Anesth Analg. 1971;50:222–226.
- Holzgrafe RE, Vondrell JJ, Mintz SM. Reversal of postoperative reactions to scopolamine with physostigmine. Anesth Analg. 1973;52:921–925.
- Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35:374–381.
- Krenzelok EP. Aspects of Datura poisoning and treatment. Clin Toxicol. 2010;48:104–110.
- Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9:588–590.
- Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium – theory, evidence and practice. Br J Clin Pharmacol. 2016;81:516–524.
- Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Toxicology Investigators Consortium investigators, et al. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11:179–184.
- Olson KR, editor. Poisoning & drug overdose. 6th ed. New York, NY: McGraw-Hill Companies Inc; 2007.
- Suchard JR. Assessing physostigmine's contraindication in cyclic antidepressant ingestions. J Emerg Med. 2003;25:185–191.
- Kulig K, Rumack BH. Physostigmine and asystole. Ann Emerg Med. 1981;10:228–220.
- Knapp S, Wardlow ML, Albert K, et al. Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos. 1991;19:400–404.
- Hartvig P, Wiklund L, Lindström B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol Scand. 1986;30:177–182.
- Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev. 1998;4:87–136.
- Asthana S, Greig NH, Hegedus L, et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther. 1995;58:299–309.